In addition, clinical data indicate that elevated total eIF4E levels along with increased phosphorylation of 4EBP1 is associated with disease progression and poor patient survival in breast, prostate and ovarian cancers.. This evidence concerns the gene EIF4EBP1 and ovarian carcinoma.